RxDoctor Payments Data

Sheryle Paukert

Family · Napa, CANPI 1356550008

Payments from drug & device makers

$2,797in general payments, 2019–2025

Across 101 payments — averaging $27.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$578
  • Amgen$413
  • Bayer$272
  • Vifor Pharma, Inc.$255
  • Novo Nordisk$218
  • Takeda Pharmaceuticals U.S.A., Inc.$182
  • plus $878 from 20 others

What the payments were for

  • Food & beverage$2,77699%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,797 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl20$64,981
AuryxiaFerric Citrate11$43,006
JardianceEmpagliflozin30$38,589
OzempicSemaglutide27$29,047
VeltassaPatiromer Calcium Sorbitex27$28,432
TrulicityDulaglutide25$23,912
FarxigaDapagliflozin Propanediol33$23,353
Tresiba Flextouch U-100Insulin Degludec32$16,731
Sevelamer Carbonate23$7,358
Calcium Acetate36$2,357
Nifedipine ErNifedipine17$1,037
Telmisartan21$890
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$796
Hydralazine Hcl37$796
Olmesartan Medoxomil83$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Akebia Therapeutics IncAuryxia$18$43,00611 claims
Boehringer IngelheimJardiance$124$38,58930 claims
Novo NordiskOzempic$218$29,04727 claims
Lilly USA, LLCTrulicity$25$23,91225 claims
AstraZenecaFarxiga$578$23,35333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Napa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →